BioWorld

April 23, 2008

Resolvyx Adds $25M to Move First Resolvin Drugs into Clinic

Gearing up to move its first two drug candidates into the clinic this year, Resolvyx Pharmaceuticals Inc. padded its bank account with a $25 million Series B round from new and existing investors. (BioWorld Today) Read More

Congress Told Foreign Plants are 'Ticking Time Bombs'

'Pseudokinase' Found Active, Without Binding Magnesium

CuraGen Sells Cancer Drug to TopoTarget for $45M

Genzyme Must File 2 BLAs for Myozyme Formulations

Theravance Cuts Staff 40%; Telavancin Inches Along

FDA Approves Cimzia for Crohn's Disease

Spectrum Shares Falls on Ozarelix Miss

ImClone, BioVex Secure SPAs For Late-Stage Cancer Studies

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 16, 2025.

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

BioWorld

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...